Core Viewpoint - Yinosh successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, becoming the first central enterprise CRO in China, highlighting its leadership in the non-clinical research service sector and its significant market share in non-clinical safety evaluation [1][2]. Company Performance - In 2024, Yinosh achieved a revenue of 1.142 billion yuan, a year-on-year growth of 9.94%, with non-clinical CRO business revenue exceeding 1 billion yuan [2]. - The company reported a net profit of 148 million yuan, with a non-recurring net profit of 125 million yuan [2]. - The non-clinical CRO business generated 1.089 billion yuan in revenue, growing by 8.99%, while the clinical CRO business saw a revenue increase of 27.17%, reaching 46.9385 million yuan [2]. Strategic Focus - Yinosh emphasizes a customer-centric approach and focuses on core business areas, enhancing its competitive edge through innovation and reform [1][3]. - The company is expanding its laboratory scale and introducing advanced equipment, supported by the broadened financing channels post-listing [2]. R&D Investment - Yinosh has consistently increased its R&D investment, reaching 60.5325 million yuan in 2024, reflecting its commitment to scientific leadership [3][4]. Market Positioning - The company is positioned as a leader in non-clinical safety evaluation, providing solutions for emerging drug development directions, including multi-specific antibodies and gene therapies [4][5]. - Yinosh has established a differentiated competitive advantage through unique service platforms and customized solutions tailored to specific drug characteristics [5]. Global Strategy - Yinosh is actively pursuing a global strategy, with a focus on international collaboration and market expansion, aiming to enhance its service capabilities and contribute to global health [6]. - The company anticipates a significant increase in the number of innovative drug candidates sourced from China, projecting that this could exceed 50% in the near future [6].

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

Group 1 - The CRO (Contract Research Organization) sector is experiencing a significant rise, with Chengdu Xian Dao hitting the daily limit up [1] - MediXci and Hai Te Biological have increased by over 14%, indicating strong market interest [1] - Other companies such as Zhao Yan New Drug, Yi Nuo Si, Yang Guang Nuo He, Kang Long Hua Cheng, and Pu Rui Si are also seeing gains, reflecting a broader trend in the sector [1] Group 2 - There is a notable influx of dark pool funds into these stocks, suggesting increased investor confidence and potential for further growth [1]

本次利润分配方案经公司2025 年 6 月 12 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 证券代码：688710 证券简称：益诺思 公告编号：2025-023 上海益诺思生物技术股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/22 | 2025/7/23 | 2025/7/23 | 一、 通过分配方案的股东大会届次和日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本140,979,615股为基数，每股派发现 金红利0.32元（含税），共计派发现金红利45,113,476.80元。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0 ...

Market Overview - The Shanghai Composite Index closed at 3496.32 points, above the five-day moving average, with an increase of 0.67% [1] - The total trading volume of A-shares reached 11533.72 billion yuan [1] Stocks Performance - A total of 1698 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Yitong New Materials (300930) with a deviation rate of 13.85% and a daily increase of 19.99% [1] - Shouhang New Energy (301658) with a deviation rate of 13.72% and a daily increase of 20.00% [1] - Chuanjin Nuo (300505) with a deviation rate of 11.72% and a daily increase of 15.83% [1] Additional Notable Stocks - Other stocks with significant performance include: - Longmag Technology (300835) with a deviation rate of 10.45% and a daily increase of 13.35% [1] - Ainengju (834770) with a deviation rate of 9.51% and a daily increase of 15.84% [1] - Yinos (688710) with a deviation rate of 9.02% and a daily increase of 11.45% [1]

证券代码：688710 证券简称：益诺思 公告编号：2025-022 上海益诺思生物技术股份有限公司 关于控股子公司拟进行业务调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 控股子公司业务调整概述 为进一步优化上海益诺思生物技术股份有限公司（以下简称"公司""上海 益诺思"）产能配置，降低管理成本，提高管理效率和管控能力，结合公司控股 子公司深圳市益诺思生物医药安全评价研究院有限公司（以下简称"深圳益诺 思"）实际经营情况，深圳益诺思将进行业务调整，除存续业务以外不再承接新 业务；同时公司募集资金投资项目（以下简称"募投项目"）已按计划顺利推进， 全资子公司益诺思生物技术南通有限公司（以下简称"南通益诺思"）所实施的 募投项目"高品质非临床创新药物综合评价平台扩建项目"将逐步投入使用，后 续新增业务将由上海益诺思及南通益诺思承接。 二、 控股子公司基本情况 （一）基本情况 1、公司名称：深圳市益诺思生物医药安全评价研究院有限公司 2、成立时间：2021 年 11 月 9 日 3、注册资本：2,000 万元 ...

Core Viewpoint - The company is optimizing its capacity allocation and management efficiency by adjusting the business operations of its subsidiary, Shenzhen Yinos Bio-pharmaceutical Safety Evaluation Research Institute Co., Ltd, which will no longer undertake new business except for existing operations [1] Financial Summary - Shenzhen Yinos was established in November 2021 with a registered capital of 20 million yuan [1] - As of 2024, the total assets of the company were 115 million yuan, with a net asset value of -64.87 million yuan, operating revenue of 65.71 million yuan, and a net profit of -21.50 million yuan [1] - By March 31, 2025, the total assets decreased to 105 million yuan, net assets further declined to -71.61 million yuan, operating revenue dropped to 14.92 million yuan, and net profit improved slightly to -6.73 million yuan [1]

证券代码：688710 证券简称：益诺思 公告编号：2025-021 上海益诺思生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 12 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号中 心报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 64 | | --- | --- | | 普通股股东人数 | 64 | | 2、出席会议的股东所持有的表决权数量 | 96,448,952 | | 普通股股东所持有表决权数量 | 96,448,952 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.4134 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.4134 | （ ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN HONG KONG PARIS MADRID SILICON VALLEY 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 2024 年年度股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 ...

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2024 年年度股东大会会议资料 上海益诺思生物技术股份有限公司 2024 年年度股东大会 会议资料 二〇二五年六月 | 2024年年度股东大会须知 3 | | | --- | --- | | 2024年年度股东大会会议议程 | 5 | | 议案一：关于公司《2024年度董事会工作报告》的议案 6 | | | 议案二：关于公司《2024年度监事会工作报告》的议案 14 | | | 议案三：关于公司《2024年度财务决算报告》的议案 19 | | | 议案四：关于公司《2025年度财务预算报告》的议案 24 | | | 议案五：关于公司《2024年年度报告》及摘要的议案 26 | | | 议案六：公司2024年度利润分配方案 | 27 | | 听取事项：公司独立董事2024年度述职报告 | 28 | 2024年年度股东大会须知 根据中国证券监督管理委员会相关规则和《公司章程》的有关规定，为确 保公司股东大会顺利召开，特制定大会须知如下，望出席股东大会的全体人员 遵守执行： 一、公司董事会办公室具体负责大会有关程序、资料相关的事宜。 二、股 ...